Evidence map›Paper›PMID 39160175›Full record

ArticleScientific reports2024

Carbapenem-resistant Acinetobacter baumannii (CRAB): metabolic adaptation and transcriptional response to human urine (HU).

Jenny Escalante, Mase Hamza, Brent Nishimura, Meghan Melecio, Carol Davies-Sala, Marisel R Tuttobene, Tomás Subils, German M Traglia, Chloe Pham, Rodrigo Sieira and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Temporal Trends in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Jenny Escalante *Center for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, 800 N State College Blvd, Fullerton, CA, USA.
Mase Hamza *Center for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, 800 N State College Blvd, Fullerton, CA, USA.
Brent NishimuraCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, 800 N State College Blvd, Fullerton, CA, USA.
Meghan MelecioCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, 800 N State College Blvd, Fullerton, CA, USA.
Carol Davies-SalaCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, 800 N State College Blvd, Fullerton, CA, USA.
Marisel R TuttobeneÁrea Biología Molecular, Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario, Argentina.
Tomás SubilsInstituto de Procesos Biotecnológicos y Químicos de Rosario (IPROBYQ, CONICET-UNR), Rosario, Argentina.
German M TragliaUnidad de Genómica y Bioinformática, Departamento de Ciencias Biológicas, CENUR Litoral Norte, Universidad de la República, Montevideo, Uruguay.
Chloe PhamCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, 800 N State College Blvd, Fullerton, CA, USA.
Rodrigo SieiraFundación Instituto Leloir-IIBBA CONICET, Buenos Aires, Argentina.
Luis A ActisDepartment of Microbiology, Miami University, Oxford, Ohio, USA.
Robert A BonomoResearch Service and GRECC, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, OH, USA.
Marcelo E TolmaskyCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, 800 N State College Blvd, Fullerton, CA, USA.
María Soledad RamirezCenter for Applied Biotechnology Studies, Department of Biological Science, College of Natural Sciences and Mathematics, California State University Fullerton, 800 N State College Blvd, Fullerton, CA, USA. msramirez@fullerton.edu.

Funding

Understanding B-Lactam Resistance in Acinetobacter baumanniiR01AI072219 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ROBERT A. BONOMO, Philip N. Rather · 2007 to 2026
$6.6M
Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
A Mechanism-Based Approach to Metallo-beta-Lactamase InhibitionR01AI100560 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A., SPENCER, JAMES · 2012 to 2022
$4.4M
Minority Health and Health Disparities International Research Training ProgramT37MD001368 · NIMHD · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2005 to 2024
$3.9M
DEALING WITH ANTIBIOTIC RESISTANCE--ANTISENSE TECHNOLOGYR15AI047115 · NIAID · CALIFORNIA STATE UNIVERSITY FULLERTON · PI TOLMASKY, MARCELO E · 2000 to 2022
$1.8M
Identifying host human products responsible for natural transformation of resistance traits in Acinetobacter sppSC3GM125556 · NIGMS · CALIFORNIA STATE UNIVERSITY FULLERTON · PI RAMIREZ, MARIA SOLEDAD · 2018 to 2025
$851k
The Continuing Challenge of Carbapenemases in K. pneumoniae: KPC-2 & NDM-1I01BX001974 · VA · LOUIS STOKES CLEVELAND VA MEDICAL CENTER · PI BONOMO, ROBERT A. · 2013 to 2024
–
BLRD VA I01 BX001974Cleveland Department of Veterans Affairs 1I01BX001974NIAID NIH HHS R01 AI063517NIAID NIH HHS R01 AI072219NIAID NIH HHS R01 AI100560NIAID NIH HHS R15 AI047115NIGMS NIH HHS SC3 GM125556NIH HHS 2R15 AI047115NIH HHS 2T37MD001368NIH HHS R01AI100560, R01AI063517, R01AI072219NIH HHS SC3GM125556NIMHD NIH HHS T37 MD001368
6 · The paper itself

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a major human pathogen and a research priority for developing new antimicrobial agents. CRAB is a causative agent of a variety of infections in different body sites. One of the manifestations is catheter-associated urinary tract infection, which exposes the bacteria to the host's urine, creating a particular environment. Exposure of two CRAB clinical isolates, AB5075 and AMA40, to human urine (HU) resulted in the differential expression levels of 264 and 455 genes, respectively, of which 112 were common to both strains. Genes within this group play roles in metabolic pathways such as phenylacetic acid (PAA) catabolism, the Hut system, the tricarboxylic acid (TCA) cycle, and other processes like quorum sensing and biofilm formation. These results indicate that the presence of HU induces numerous adaptive changes in gene expression of the infecting bacteria. These changes presumably help bacteria establish and thrive in the hostile conditions in the urinary tract. These analyses advance our understanding of CRAB's metabolic adaptations to human fluids, as well as expand knowledge on bacterial responses to distinct human fluids containing different concentrations of human serum albumin (HSA).

Indexed as

Acinetobacter baumanniiCarbapenemsUrineAcinetobacter InfectionsAdaptation, PhysiologicalAnti-Bacterial AgentsBiofilmsDrug Resistance, BacterialGene Expression Regulation, BacterialHumansUrinary Tract InfectionsAnti-Bacterial AgentsCarbapenemsAcinetobacter baumanniiCarbapenem-resistanceHuman serum albuminHuman urine

Identifiers

PMID39160175
PMCPMC11333713

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.